NYSE:SYN
Delisted
Synthetics Biologics Inc Stock News
$0.91
+0.0050 (+0.556%)
At Close: Jan 27, 2023
Synthetic Biologics, Inc. (SYN) CEO Steven Shallcross on Q2 2022 Results - Earnings Call Transcript
12:19pm, Thursday, 11'th Aug 2022
Synthetic Biologics, Inc. (NYSE:SYN ) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET Company Participants Chris Calabrese - Investor Relations Steven Shallcross - Chief Executive & Chief
Synthetic Biologics, Inc. (SYN) CEO Steven Shallcross on Q1 2022 Results - Earnings Call Transcript
05:06pm, Monday, 16'th May 2022
Synthetic Biologics, Inc. (NYSE:SYN ) Q1 2022 Earnings Conference Call May 16, 2022 9:00 AM ET Company Participants Dean Schwartz - LifeSci Advisors, IR Steven Shallcross - CEO and CFO Manel Cascallo
ROCKVILLE, Md., May 09, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of hig
5 Top Biotech Penny Stocks Under $1 To Watch This Week
01:45pm, Tuesday, 19'th Apr 2022
Top penny stocks to watch under $1 in April if you like Biotech stocks. The post 5 Top Biotech Penny Stocks Under $1 To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Informati
Synthetic Biologics, Inc. (SYN) CEO Steven Shallcross on Q4 2021 Results - Earnings Call Transcript
11:09pm, Wednesday, 16'th Mar 2022
Synthetic Biologics, Inc. (SYN) CEO Steven Shallcross on Q4 2021 Results - Earnings Call Transcript
Synthetic Biologics FY 2021 Earnings Preview
09:35pm, Tuesday, 15'th Mar 2022 Seeking Alpha
Synthetic Biologics (NYSE:SYN) is scheduled to announce FY earnings results on Wednesday, March 16th, after market close.The consensus EPS Estimate is -$0.10 (+84.8% Y/Y) and the…
Top-notch Stock: Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), Synthetic Biologics, Inc. (AMEX:SYN)
09:48am, Monday, 14'th Mar 2022 Stock Equity
Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) with the stream of -1.83% also noticed, India Synthetic Biologics, Inc. (AMEX:SYN) encountered a rapid change of -4.77% in the last hour of Friday’s trading session. … The post Top-notch Stock: Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), Synthetic Biologics, Inc. (AMEX:SYN) appeared first on Stocks Equity .
Synthetic Biologics to Host Conference Call and Webcast to Discuss 2021 Year End Operational Highlights and Financial Results
04:30pm, Thursday, 10'th Mar 2022
ROCKVILLE, Md., March 10, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of h
Stock on fire: Infinity Pharmaceuticals, Inc. (NASDAQ:INFI), Synthetic Biologics, Inc. (AMEX:SYN)
04:45am, Tuesday, 08'th Mar 2022 Stock Equity
Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) with the stream of -2.44% also noticed, India Synthetic Biologics, Inc. (AMEX:SYN) encountered a rapid change of 0.21% in the last hour of Monday’s trading session. … The post Stock on fire: Infinity Pharmaceuticals, Inc. (NASDAQ:INFI), Synthetic Biologics, Inc. (AMEX:SYN) appeared first on Stocks Equity .
NEW YORK, United States, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Facts and Factors has published a new research report titled "Irritable Bowel Syndrome (IBS) Diagnostics Market By Type (IBS-C, IBS-D and Mixed IBS), By Product (Rifaximin, Eluxadoline, Lubiprostone, Linaclotide, & Others), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, & Online Pharmacies), and By Regions Global & Regional Industry Perspective, Comprehensive Analysis, and Forecast, 2021 2026" in its research database. "According to the latest research study, the demand of global Irritable Bowel Syndrome (IBS) Diagnostics Market size & share was valued at approximately USD 1.2 Billion in 2020 and is expected to reach a value of around USD 2.3 Billion by 2026, at a compound annual growth rate (CAGR) of about 9.7% during the forecast period 2021 to 2026." What is Irritable Bowel Syndrome (IBS) Diagnostics? How big is the Irritable Bowel Syndrome (IBS) Diagnostics Market? Market Overview & Coverage: Irritable bowel syndrome is a medical condition that pertains to irregular bowel movement and is accompanied by extreme pain in the stomach followed by diarrhoea, cramping, and constipation among others.
Synthetic Biologics to Present at 2022 BIO CEO & Investor Conference
07:15am, Wednesday, 09'th Feb 2022
ROCKVILLE, Md., Feb. 9, 2022 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high
Synthetic Biologics says VCN''s therapy for retinoblastoma gets FDA''s orphan drug status
01:00pm, Tuesday, 08'th Feb 2022 Seeking Alpha
Synthetic Biologics (SYN) said VCN Biosciences'' VCN-01 received the U.S
Synthetic Biologics Announces VCN Biosciences'' VCN-01 Receives Orphan Drug Designation for Retinoblastoma from the U.S. FDA
12:15pm, Tuesday, 08'th Feb 2022 PR Newswire
ROCKVILLE, Md., Feb. 8, 2022 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced that VCN Biosciences, S.L.''s (VCN) VCN-01 received Orphan Drug…
47 Biggest Movers From Yesterday
09:53am, Tuesday, 08'th Feb 2022 Benzinga
Gainers Nuvectis Pharma, Inc. (NASDAQ: NVCT ) shares surged 144.6% to close at $7.95 on Monday. The company, on Friday, priced its IPO at $5 per share. Anghami Inc. (NASDAQ: ANGH ) shares climbed 62.5% to close at $19.50 following its recent listing on NASDAQ. Kaival Brands Innovations Group, Inc. (NASDAQ: KAVL ) surged 51.4% to settle at $1.62. Kaival Brands Innovations recently announced the U.S. Court of Appeals for the Eleventh Circuit has granted a judicial stay of the marketing denial order previously issued by the FDA to Bidi Vapor in September 2021. Origin Agritech Limited (NASDAQ: SEED ) gained 34.5% to settle at $6.39 after the company said it expects FY22 sales to exceed RMB150 million. Bakkt Holdings, Inc. (NASDAQ: BKKT ) shares jumped 34% to close at $5.80. Luokung Technology Corp. (NASDAQ: LKCO ) gained 24.3% to close at $0.63. Luokung recently announced the receipt of Nasdaq notification regarding minimum bid price deficiency. Navidea Biopharmaceuticals, Inc. (NYSE: NAVB ) surged 23.2% to settle at $0.8870 after the company announced a research agreement with the University of Pennsylvania evaluating Tc99m tilmanocept as a prognostic marker for glioblastoma.
Synthetic Biologics Inc. Shares Close in on 52-Week Low - Market Mover
11:34pm, Thursday, 13'th Jan 2022 Kwhen Finance
Synthetic Biologics Inc. (SYN) shares closed today at 2.0% above its 52 week low of $0.26, giving the company a market cap of $36M. The stock is currently up 2.3% year-to-date, down 68.2% over the past 12 months, and down 99.1% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 rose 0.6%. Trading Activity Trading volume this week was 55.5% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.4. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 258.5% The company's stock price performance over the past 12 months lags the peer average by -729.4%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.